超声引导下经直肠植入125l粒子在前列腺癌治疗中的应用-影像医学与核医学专业论文.docxVIP

PAGE PAGE 5 System ，丁PS )制定计划:采用经直肠超声( Transrectal Ultrasonography，TRUS) 引导穿刺从直肠途径将叫粒子植入前列腺实施治 疗方案，并同时行双侧罪丸切除泊疗:术后 α 扫描王维章建，进行粒子分 布情况的判断并评估剂量分布，定期随访患者 PSA、前列腺体积和并发症 ‘ ， 情况。对照组 40 例实施双侧翠丸切除术。 82 例患者术后同时服用比卡鲁 ? 胶内分泌化疗药物。结果:实验组 42 例患者手术过程顺利，均按照定计划 完成，植入粒子 22 (1050) 颗，无因经直肠穿刺引起的严重并发症:术 后运用 CT 扫描见粒子分布符合预定计划;剂量分布评估较为满意。术后 随访 24才8 个月，中位随访时间 36.6 个月。 1 例术后 16 个月发生骨转移， 2 例在术后平均 18.6 个月出现 PSA 生化复发，累计 PSA 无进展患者生存 率为 92.8%。对照组中l 例于术后 23 个月死亡， 3 例在术眉 14 个月发生骨 转移，有 5 例在术后平均 15.8 个月出现 PSA 生化复发，累计 PSA 无进展 患者生存率为 77.悦。结论采用 TRUS 引导下经直肠植入 125r 放射粒子技术 安全可靠，操作简便，有效缩短了手术时间。粒子植入联合手术去势治疗 局部晚期前列腺癌是一种有效的治疗方法，值得推广。 关键询: 直肠超声经直肠穿刺植入 叫粒子前列腺癌 内分泌治疗 Transrectal Implantation Of 1251Particles In The Treatment Of Prostate Cancer Abstract: bjective: Prostate cancer(PCa) as men in many Westem countries，the most common malignancy ，accounting for U.S. men in 2006 the J second cause of cancer death. Since prostate-specific antigen (PSA) ? examination start时， since the early 90s to mid-century found significantly higher incidence of PCa. Although the low incidence of PCa，but in recent years as the population ages and the improvement of living conditions，the incidence rate increased rapidly，in our male urinary and reproductive system cancer incidence rates in the ranks third. PCa has become of our men，especially men over 50 years of age an important factor in health，due to occult PCa incidence and the current inspection of PSA is not yet universal primary health care sector， endocrine therapy is currently the main treatment ，but has its limitations ，so most of the time already in advanced PCa detection，to clinical treatment with to the difficulty，80 how to choose the best treatment is our common goal. Recent years，with new，low energy，safe，easy protection for the 8uccessful development of radionuclides 1251，real-time positioning accuracy of transrectal ultrasound ，CT imaging technology matures and computer three-dimensional radiotherapy treatment planning